Pancreatic cancer is one of the hardest cancers to treat. 50,000 people are diagnosed with it in the U.S. each year, with about 40,000 of them dying from the disease annually. The one year survival rate is an abysmal 29% and only 1% survive past 5 years. A new oral cancer drug RX-3117 from Rexahn Pharmaceuticals offers hope and efficacy where other drugs have failed.
– The Bio Connection –